Correspondence
- PMID: 34001818
- DOI: 10.1097/IAE.0000000000003211
Correspondence
Comment in
-
Reply.Retina. 2021 Sep 1;41(9):e65-e66. doi: 10.1097/IAE.0000000000003212. Retina. 2021. PMID: 34001819 No abstract available.
Comment on
-
COMPARISON OF INTRAVITREAL DEXAMETHASONE IMPLANT AND AFLIBERCEPT IN PATIENTS WITH TREATMENT-NAIVE DIABETIC MACULAR EDEMA WITH SEROUS RETINAL DETACHMENT.Retina. 2020 Jun;40(6):1044-1052. doi: 10.1097/IAE.0000000000002537. Retina. 2020. PMID: 30950970 Clinical Trial.
References
-
- Ozsaygili C, Duru N. Comparison of intravitreal dexamethasone implant and aflibercept in patients with treatment-naive diabetic macular edema with serous retinal detachment. Retina 2020;40:1044–1052.
-
- Bakbak B, Ozturk BT, Gonul S, Gedik S. The effect of intravitreal bevacizumab and ranibizumab on macular edema of the contralateral eye: a comparative study of two anti-VEGFs. Oman J Ophthalmol 2016 ;9:44–48.
-
- Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 2014 ;98:1636–1641.
-
- Choi M, Jee D, Kwon J. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS One 2019;14:e0222364.
-
- Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intra-vitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843–1851.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
